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Objectives: In 2010, the US Advisory Committee on Immunization Practices recom-
mended 7-valent pneumococcal conjugate vaccine (PCV7) be replaced by 13-valent 
vaccine (PCV13) for routine use in a four-dose series at 2, 4, 6, and 12-15 months of 
age. Published analyses estimated that PCV13 implementation would be cost-saving 
in aggregate, but the net economic impact on particular payers is unknown. We 
disaggregated the expected costs and savings by payer to determine the net costs for 
public and private payers over a 10-year horizon. MethOds: A Markov model was 
used to simulate vaccination and pneumococcal disease events and their related 
costs with PCV13 compared to PCV7 from 2010 to 2019. The PCV13 strategy included 
a one-time catch-up dose in 2010 for children who had completed the PCV7 series. 
Disease reductions both in vaccinated and other age groups were modeled based 
on PCV7 efficacy and effectiveness data. Medical costs related to pneumococcal 
disease were allocated to public (Medicare; Medicaid; military) or private payers 
using age-specific health care insurance coverage survey data. Vaccine program 
costs were allocated based on sales data. All costs were measured in 2013 US dol-
lars. Results: In the simulation, 40.3 million(M) children participated in routine 
vaccination while 5.8M received a catch-up dose in the PCV13 strategy. The PCV13 
strategy prevented an additional 121,300 cases of invasive pneumococcal disease, 
3.3M of pneumonia and 17.6M of acute otitis media compared to PCV7 over 10 years. 
Public and private payers will pay $3.5 billion(B) and $2.6B, respectively, for the vac-
cine but accrue $6.1B and $4.2B in overall savings. While the magnitude of savings 
varied in sensitivity analyses, implementation of PCV13 remained cost-saving for 
all payers. cOnclusiOns: The currently-recommended PCV13 pediatric program 
is cost-saving for both public and private payers. Net savings were greater for public 
payers, despite higher vaccine costs.
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Objectives: To estimate the budgetary impact of adding dolutegravir to the Ontario 
Drug Benefit Formulary (ODBF) for a three-year period for the treatment of HIV 
infection in adults and children (≥ 12 years of age). MethOds: Three discrete popu-
lations were considered: treatment-naïve (TN) patients staying on their first line, 
TN switchers (assumed switches within the first 6 months of antiretroviral therapy 
(ART) initiation) and treatment-experienced (TE) patients. Epidemiology data were 
obtained from published sources. Ontario-specific data and analysis from the IMS 
Brogan Database were used to estimate the proportion of patients who were treated 
and covered by the ODBF, proportions of patients remaining on their first regi-
men after ART initiation over time, comparators and historical market share data. 
ART drug costs were calculated based on the dosage of each regimen component 
from the respective product monographs and unit costs from the ODBF. The budget 
impact was calculated for the whole HIV population and separately for each popula-
tion. Sensitivity analyses were conducted on five key input parameters. Results: 
Out of the 12 comparators, dolutegravir-containing regimens were assumed to take 
market shares from 6 regimens: Atripla, Truvada⁄Prezista⁄Norvir, Truvada⁄Isentress, 
Truvada⁄Reyataz⁄Norvir, Kivexa⁄Isentress and Stribild. Adding dolutegravir to the list 
of reimbursed ARTs on the ODBF will result in incremental savings in each of the 
three years following the listing date of $2,717,585, $5,181,704, and $8,040,076 for a 
total savings of $15,939,365. The analysis was somewhat sensitive to assumptions 
made regarding HIV incidence and prevalence and the proportion treated with drug 
benefits. Based on the accuracy of the assumptions made in this analysis, the total 
savings to the budget over a three-year period may range between $12,751,492 and 
$19,127,238. cOnclusiOns: The addition of adding dolutegravir to the ODBF will 
result in a significant net savings through the displacement of more expensive 
regimens in Ontario.
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Objectives: The prevalence of systemic Candida infection (SCI) caused by non-albi-
cans species, which display greater resistance to azole antifungal agents, is increas-
ing. Treatment with broad-spectrum antifungal agents, such as echinocandins, with 
subsequent switch to fluconazole if isolates are shown to be sensitive (‘de-escala-
tion’) is recommended by treatment guidelines. We developed a model to assess the 
budget impact of the de-escalation strategy in France and Germany. MethOds: The 
budget impact of initial micafungin treatment in a de-escalation strategy versus 
fluconazole in an escalation strategy was modelled using decision analysis based on 
data from relevant studies and a cost-effectiveness analysis. Duration of appropriate 
treatment was 14 days, meaning that treatment outcome was assessed after 14 days, 
or 17 days if fluconazole had to be switched once fluconazole sensitivity was known 
(after 3 days of therapy). Clinical success was defined as resolution or reduction of all 
signs, symptoms and radiographic abnormalities associated with SCI at treatment 
end. Results: In France and Germany, the incidence of SCI was estimated at 28 
Objectives: Azithromycin has an attractive safety profile in treating or preventing 
certain bacterial infections. However, there is growing concern that Azithromycin 
may be associated with increased cardiovascular risk and lead to cardiovascu-
lar death in high risk patients. We therefore conducted a meta-analysis of rand-
omized Controlled trials to describe the cardiovascular risk profile of those patients 
receiving Azithromycin. MethOds: The MEDLINE and Cochrane Central Register 
of Controlled Trials databases were searched from 1991 to September 2013 using 
specific search terms for English-language trials of comparing high baseline risk 
of cardiovascular disease patients receiving Azithromycin or placebo and have 
reported cardiovascular outcomes. Abstracts from major scientific meetings were 
also reviewed.In the analysis, Methods based on odds ratios (ORs) was used. OR was 
calculated using a random-effects model (because we assume that the treatment 
effect in all the included studies are not identical) from the ORs and 95% confidence 
intervals (CIs) were used for each end point in each study. Statistical heteroge-
neity scores were assessed with an I42test. Sensitivity analyses were performed 
by removing some trials and recalculating the combined ORs for the remaining 
studies. Results: 12 trials randomized a total of 15,588 patients into two groups, 
treatment and placebo. Treatment effect on any cardiovascular outcome was not sig-
nificantly different in any of the nine trials. For all trials combined, the pooled odds 
ratio for mortality was not significantly different [(OR, 0.873; 95% CI, 0.743–1.027), p 
= 0.102]. No heterogeneity was observed (I2= 0). Similarly, there was no difference 
in the pooled odds ratio for hospitalization and coronary intervention [(OR, 1.021; 
95% CI, 0.882–1.182), p = 0.774, I2= 0%] and [(OR, 0.998; 95% CI, 0.885–1.125), p = 0.982, 
I2= 0%], respectively. cOnclusiOns: The findings of this systematic review suggest 
that no significant relationships exist between Azithromycin and risk of cardiovas-
cular events in high risk patients.
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Objectives: Patients in the intensive care unit (ICU) have multiorgan dysfunction 
as well as altered pharmacokinetic parameters. Hence, they are more susceptible to 
adverse drug reactions (ADRs). The objective of the study was to identify the major 
class of drugs involved in causing ADRs in ICU patients of an Indian public teaching, 
tertiary care hospital. MethOds: A prospective observational study was conducted 
in the ICUs of a public teaching hospital. All the relevant data was collected from 
the patients case records in a standard data collection format and the patients 
were followed until discharge or transferred from the ICUs. ADRs were identified 
based on the subjective findings, objective findings and spontaneous reporting. The 
drugs responsible for causing ADR were identified and classified using Anatomic, 
Therapeutic and Chemical(ATC) classification. Results: The results of this 12 week 
study were based upon the data obtained from 70 patients(37 males, 33 females). 
Only 10 patients developed ADRs. The drugs causing ADRs were classified using the 
ATC classification. This showed that the most common ADR causing drugs belonged 
to the class of infections and infestations (30%), cardiovascular system(14%), endo-
crine system(14%), respiratory system (14%) and others (14%), followed by Brain 
and nervous system (7%), blood and blood forming agents (7%) accounting for least 
number of ADRs. cOnclusiOns: In this pilot study, Antimicrobials was found to 
be the most common class of drugs causing ADRs. We studied small number of 
patients, it is suggested that future large scale studies should be done to further 
gain insight into the ADRs.
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Objectives: Higher plasma CD4 cell counts per mm3 at ART initiation (AI-CD4) 
improve long-term CD4 responses and survival. Recent data suggest CD4 > 750 is a 
clinically significant threshold for AIDS-related illness reduction and immune “nor-
malization”. We evaluated the effect of AI-CD4 on achieving CD4 > 750 and mortality 
risk. MethOds: Among HIV Outpatient Study patients seen during 1996-2012 for 
three or more years after AI, we analyzed CD4 trajectories and mortality rates per 
100 persons-years (MR) by AI-CD4, and the association of AI-CD4 with achieving CD4 
> 750 (“normalization”) using Kaplan-Meier methods and Cox proportional hazards 
models. Results: Of 1327 eligible patients followed a median of 7.9 years, > 85% 
received HAART ≥ 75% of follow-up time, and 64 died. Higher AI-CD4 was associated 
with increased median peak CD4 (p < 0.001). Maximal CD4 response and benefit 
plateaued at eight years, but differences by AI-CD4 persisted (p < 0.001). Lower 
crude MRs (p = 0.005) and higher CD4 closest to death (p = 0.013) were associated 
with higher AI-CD4. Increases in median CD4 for persons with AI-CD4 < 50 and 
50-199 converged by eight years (< 50% achieved CD4 > 750) whereas patients with 
AI-CD4 > 350 normalized by eight years (> 80% of patients). In multivariable analy-
ses, higher AI-CD4 was the only factor independently associated with achieving 
CD4 normalization during follow-up. cOnclusiOns: Progressively higher AI-CD4 
predicted greater long-term CD4 gains, achieving CD4 normalization, increased 
crude survival rates, and higher CD4 at death. CD4 gains and chances of reaching 
CD4 normalization peaked at eight years after AI. Most with AI-CD4 > 350 eventually 
achieved CD4 normalization while less than half with AI-CD4s < 50 and 50-199 did. 
AI-CD4 ≥ 500 optimized the likelihood of CD4 normalization confirming the hazards 
of delayed and support AI at CD4 ≥ 500.
